MedTrace Logo

Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

NCT01300871 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2014-09-26

No results posted yet for this study

Summary

This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).

Conditions

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Lindsay Carlsson · University Health Network-Princess Margaret Hospital

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Completion
2012-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01300871 on ClinicalTrials.gov